KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Current Assets (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Current Assets data on record, last reported at $16.5 billion in Q1 2025.

  • For Q1 2025, Current Assets fell 4.28% year-over-year to $16.5 billion; the TTM value through Mar 2025 reached $16.5 billion, down 4.28%, while the annual FY2025 figure was $16.6 billion, 6.71% down from the prior year.
  • Current Assets reached $16.5 billion in Q1 2025 per TAK's latest filing, down from $17.3 billion in the prior quarter.
  • Across five years, Current Assets topped out at $25.6 billion in Q1 2021 and bottomed at $16.5 billion in Q1 2025.
  • Average Current Assets over 5 years is $20.0 billion, with a median of $18.1 billion recorded in 2023.
  • Peak YoY movement for Current Assets: grew 13.01% in 2021, then dropped 18.77% in 2023.
  • A 5-year view of Current Assets shows it stood at $25.6 billion in 2021, then decreased by 12.92% to $22.3 billion in 2022, then decreased by 18.77% to $18.1 billion in 2023, then decreased by 4.76% to $17.3 billion in 2024, then fell by 4.28% to $16.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $16.5 billion in Q1 2025, $17.3 billion in Q1 2024, and $18.1 billion in Q1 2023.